Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy

NCT00004939 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

34

Enrollment

NIH

Sponsor class

Conditions

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Interventions

DRUG: ,4-diaminopyridine

Sponsor

National Center for Research Resources (NCRR)

Collaborators

[object Object]